UNSPSC 51124502: Clamikalant

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C19H22CLN3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 94301K998R. The term CLAMIKALANT is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule clamikalant under HS 29350090 and SITC 51580. As of Q4 2014, CLAMIKALANT remains US FDA's Preferred Term for this commodity. Clamikalant bears US NLM identifiers UMLS ID C2699336 and NCI Concept Code C77831.

SMILES: CNC(=S)NS(=O)(=O)C1=C(C=CC(=C1)CCNC(=O)C2=C(C=CC(=C2)CL)OC)OC.

UNSPSC 51124502 Clamikalant, a Commodity code, covers emergency and critical-care medications supplied to state and local health agencies, fire departments, and pharmacy benefit programs. State and local buyers use this code to procure injectable medications—epinephrine, labetalol, adenosine, diltiazem, and similar advanced life support agents—for ambulance fleets, fire rescue operations, and multi-state pharmacy benefit networks. The issuing bodies span city purchasing departments (procurement for municipal fire services), state health agencies coordinating multi-jurisdictional pharmacy programs, and regional cooperative purchasing alliances administering contracts across multiple states. Vendors supply finished pharmaceuticals through direct contracts with municipalities, through state-level cooperative agreements serving dozens of participating jurisdictions, or through pharmacy benefit programs operated by state health commissions.

Recent activity clusters in Florida and Texas, with multi-state coordination through Minnesota-based purchasing cooperatives serving Oregon and other participating states. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26-P-00188, due April 8, 2026, $40,000 estimated value) for Tampa Fire Rescue, requiring 370 units of Labetalol HCI 100mg, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg with nine-month minimum shelf life and ten-day delivery; this procurement offered a 5 percent bid discount for Small Local Business Enterprise participation not to exceed $10,000. The Texas Health and Human Services Commission issued RFI No. HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating states through three authorized wholesalers, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 10 percent combined on administrative compliance and EDI capability.